Evangelos Giamarellos-Bourboulis

Evangelos is Professor of Internal Medicine and Infectious Diseases at the Medical School of the National and Kapodistrian University of Athens and director of the MSc program of Infectious Diseases at the University of Athens since 2018.

His main research interests are in precision immunotherapy. He has 597 publications in international peer-reviewed journals with more than 45,000 citations and h-index 97.

He is the current Chair of the European Sepsis Alliance and President of the Hellenic Society of Chemotherapy. He is the lead investigator of the SAVE and SAVE-MORE trials, which paved the approval of anakinra for COVID-19 pneumonia by the European Medicines Agency and the US Food and Drug Administration. He is the lead investigator of the ImmunoSep trial, which provides proof-of-concept that targeted treatment may reverse the immune dysfunction by the sepsis endotypes of macrophage activation and immunoparalysis and improve outcomes.